Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease.
Notification of the decision to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No. 2986316. The company previously reported it had received notification from the European Patent Office of the intent to grant in July last year (ASX announcement July 7, 2022).
The European registration adds to Immuron's patent position for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease in Australia, New Zealand and the United States.
https://finance.yahoo.com/news/immuron-receives-european-patent-drug-121000907.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.